N@N

CellCyte Genetics Corporation Appointments Fred Mill as Vice President of Manufacturing

^{Published on 2010-09-30 06:11:34 - Market Wire}
 

BELLEVUE, Wash.--([ BUSINESS WIRE ])--CellCyte Genetics Corporation (OTCBB: [ CCYG ]) announced today the appointment of Fred Mill to the position of Vice President of Manufacturing, effective August 3, 2010. Mr. Mill will also continue in his present role of Director of Engineering, leading the ongoing development of the Companya™s CCG-E45 Culture Chamber and Incubator as new applications for the device arise. aI am very pleased to assume an expanded role in the application of CellCytea™s bioreactor product,a said Mr. Mill.

"I am very pleased to assume an expanded role in the application of CellCytea™s bioreactor product"

Fred Mill is an engineer with experience in design and manufacturing of a variety of products for the biotechnology and aerospace industry. From 1989 through 1998 he was lead design engineer for Cellpro, Inc. on their stem cell therapy products, and from 1997-2000 he was a consulting engineer for Genespan Corporation, where he was responsible for the design and manufacturing of the Cellstasis Culture Chamber and Incubator. Fred joined CellCyte in 2007 as its Director of Engineering.

CellCytea™s CCG-E45 Culture Chamber is a cell expansion device that allows the culture of cells at high density and under precisely controlled oxygenation, providing an alternative to standard cell culture methods. CellCyte is developing collaborative relationships with other independent clinical research laboratories to apply this technology to a wide range of cell expansion applications.

Mr. Mill has been CellCytea™s Director of Engineering since December 2007, and, since November of 2008, has helped refine CellCytea™s Interim Operating Plan. This Plan defines how the Company will operate with limited funding over the near term, to continue the commercialization of its bioreactor product. Mr. Milla™s appointment is the second of several planned appointments required to fully implement the Interim Operating Plan. CellCyte formally adopted the plan before the end of 2009.

aCellCyte is very fortunate to have Fred serving in this critical management role. Fred was part of the original design and manufacturing team that brought to market an earlier version of the CCG-E45 Culture Chamber and Incubator. Freda™s leadership will ensure that the CCG-E45 and subsequent clinical productivity products will meet or exceed customera™s expectations,a said John M. Fluke Jr., Chairman of the Board of Directors.

About CellCyte Genetics:

CellCyte Genetics Corporation, a Nevada corporation, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of products that enhance the productivity of biotechnology research laboratories.

Safe Harbor Statement

This news release contains "forward-looking statements", as that term is defined in section 27a of the united states securities act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical fact are forward-looking statements that state beliefs, plans, expectations or intentions regarding the future. Except for the historical information presented herein, matters discussed in this news release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "anticipate," "believe," "plan" or "expect" or similar statements are forward-looking statements. Risks and uncertainties for the company include, but are not limited to, the risks associated with the closing of the closing of the share exchange agreement and the development and funding of the company consequent thereon, as well as the risks shown in the company's most recent annual report on form 10-KSB and on form 10-QSB and from time-to-time in other publicly available information regarding the company. Other risks include risks associated with the regulatory approval process, competitive companies, future capital requirements and the company's ability and level of support for its research and development activities. There can be no assurance that the company's development efforts will succeed and the company will ultimately achieve commercial success.

These forward-looking statements are made as of the date of this news release, and the company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the company's periodic reports filed from time-to-time with the United States Securities and Exchange Commission. This news release has been prepared by management of the company who take full responsibility for its contents. Each of the NASD, the SEC and the OTCBB neither approves nor disapproves of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.